Advertisement

Diabetic Kidney Disease: Is There a Role for Glycemic Variability?

  • Savitha Subramanian
  • Irl B. Hirsch
Microvascular Complications—Nephropathy (M Afkarian and B Roshanravan, Section Editors)
Part of the following topical collections:
  1. Topical Collection on Microvascular Complications—Nephropathy

Abstract

Purpose of Review

Diabetes is the leading cause of kidney disease globally. Diabetic kidney disease (DKD) is a heterogeneous disorder manifested as albuminuria and/or decreasing GFR. Hyperglycemic burden is the major contributor to the development of DKD. In this article, we review the evidence for the contribution of glycemic variability and the pitfalls associated with use of hemoglobin A1c (A1C), the gold standard for assessment of glucose control, in the setting of DKD.

Recent Findings

Glycemic variability, characterized by swings in blood glucose levels, can result in generation of mitochondrial reactive oxygen species, a putative inciting factor for hyperglycemia-induced alterations in intracellular metabolic pathways. While there is indirect evidence supporting the role of glycemic variability in the pathogenesis of DKD, definitive data are lacking. A1C has many limitations and is a particularly suboptimal measure in patients with kidney disease, because its accuracy is compromised by variables affecting RBC survival and other factors. Continuous glucose monitoring (CGM) technology has the potential to enable us to use glucose as a more important clinical tool, for a more definitive understanding of glucose variability and its role in DKD.

Summary

Glycemic variability may be a factor in the development of DKD, but definitive evidence is lacking. Currently, all available glycemic biomarkers, including A1C, have limitations and in the setting of DKD and should be used cautiously. Emerging data suggest that personal and professional CGM will play an important role in managing diabetes in patients with DKD, where risk of hypoglycemia is high.

Keywords

Diabetes Diabetic kidney disease A1C Glycemic variability Continuous glucose monitoring Flash glucose monitoring 

Notes

Compliance with Ethical Standards

Conflict of Interest

Savitha Subramanian reports personal fees from Intarcia Pharmaceuticals and Akcea Therapeutics and grants from Ionis Pharmaceuticals.

Irl B. Hirsch reports grants from Medtronic Diabetes and Novo Nordisk and personal fees from Abbott Diabetes Care, Adocia, Intarcia, Roche, and Valeritas.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Afkarian M, Zelnick LR, Hall YN, Heagerty PJ, Tuttle K, Weiss NS, et al. Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014. JAMA. 2016;316(6):602–10.  https://doi.org/10.1001/jama.2016.10924.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    de Boer IH. A new chapter for diabetic kidney disease. N Engl J Med. 2017;377(9):885–7.CrossRefPubMedGoogle Scholar
  3. 3.
    Mayer-Davis EJ, Lawrence JM, Dabelea D, Divers J, Isom S, Dolan L, et al. Incidence trends of type 1 and type 2 diabetes among youths, 2002-2012. N Engl J Med. 2017;376(15):1419–29.  https://doi.org/10.1056/NEJMoa1610187.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Menke A, Casagrande S, Geiss L, Cowie CC. Prevalence of and trends in diabetes among adults in the United States, 1988-2012. JAMA. 2015;314(10):1021–9.  https://doi.org/10.1001/jama.2015.10029.CrossRefPubMedGoogle Scholar
  5. 5.
    Reidy K, Kang HM, Hostetter T, Susztak K. Molecular mechanisms of diabetic kidney disease. J Clin Invest. 2014;124(6):2333–40.  https://doi.org/10.1172/JCI72271.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    • Thomas MC, Brownlee M, Susztak K, Sharma K, Jandeleit-Dahm KA, Zoungas S, et al. Diabetic kidney disease. Nat Rev Dis Primers. 2015;1:15018. A comprehensive review on diabetic kidney disease.CrossRefPubMedGoogle Scholar
  7. 7.
    Pirart J. Glycaemic control and development of diabetic nephropathy. Acta Endocrinol Suppl (Copenh). 1981;242:41–2.Google Scholar
  8. 8.
    Diabetes C, Complications Trial Research G, Nathan DM, Genuth S, Lachin J, Cleary P, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977–86.  https://doi.org/10.1056/NEJM199309303291401.CrossRefGoogle Scholar
  9. 9.
    Forbes JM, Cooper ME. Mechanisms of diabetic complications. Physiol Rev. 2013;93(1):137–88.CrossRefPubMedGoogle Scholar
  10. 10.
    Kanwar YS, Wada J, Sun L, Xie P, Wallner EI, Chen S, et al. Diabetic nephropathy: mechanisms of renal disease progression. Exp Biol Med (Maywood). 2008;233(1):4–11.  https://doi.org/10.3181/0705-MR-134.CrossRefGoogle Scholar
  11. 11.
    Brasacchio D, Okabe J, Tikellis C, Balcerczyk A, George P, Baker EK, et al. Hyperglycemia induces a dynamic cooperativity of histone methylase and demethylase enzymes associated with gene-activating epigenetic marks that coexist on the lysine tail. Diabetes. 2009;58(5):1229–36.  https://doi.org/10.2337/db08-1666.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005;54(6):1615–25.  https://doi.org/10.2337/diabetes.54.6.1615.CrossRefPubMedGoogle Scholar
  13. 13.
    Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414(6865):813–20.  https://doi.org/10.1038/414813a.CrossRefPubMedGoogle Scholar
  14. 14.
    Inoguchi T, Li P, Umeda F, Yu HY, Kakimoto M, Imamura M, et al. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C--dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes. 2000;49(11):1939–45.  https://doi.org/10.2337/diabetes.49.11.1939.CrossRefPubMedGoogle Scholar
  15. 15.
    Susztak K, Raff AC, Schiffer M, Bottinger EP. Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes. 2006;55(1):225–33.  https://doi.org/10.2337/diabetes.55.01.06.db05-0894.CrossRefPubMedGoogle Scholar
  16. 16.
    Ceriello A, Esposito K, Piconi L, Ihnat MA, Thorpe JE, Testa R, et al. Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes. 2008;57(5):1349–54.  https://doi.org/10.2337/db08-0063.CrossRefPubMedGoogle Scholar
  17. 17.
    Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA. 2006;295(14):1681–7.  https://doi.org/10.1001/jama.295.14.1681.CrossRefPubMedGoogle Scholar
  18. 18.
    Wentholt IM, Kulik W, Michels RP, Hoekstra JB, DeVries JH. Glucose fluctuations and activation of oxidative stress in patients with type 1 diabetes. Diabetologia. 2008;51(1):183–90.  https://doi.org/10.1007/s00125-007-0842-6.CrossRefPubMedGoogle Scholar
  19. 19.
    Waden J, Forsblom C, Thorn LM, Gordin D, Saraheimo M, Groop PH, et al. A1C variability predicts incident cardiovascular events, microalbuminuria, and overt diabetic nephropathy in patients with type 1 diabetes. Diabetes. 2009;58(11):2649–55.  https://doi.org/10.2337/db09-0693.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Lin CC, Chen CC, Chen FN, Li CI, Liu CS, Lin WY, et al. Risks of diabetic nephropathy with variation in hemoglobin A1c and fasting plasma glucose. Am J Med. 2013;126(11):1017 e1–10.CrossRefGoogle Scholar
  21. 21.
    Sugawara A, Kawai K, Motohashi S, Saito K, Kodama S, Yachi Y, et al. HbA(1c) variability and the development of microalbuminuria in type 2 diabetes: Tsukuba Kawai Diabetes Registry 2. Diabetologia. 2012;55(8):2128–31.  https://doi.org/10.1007/s00125-012-2572-7.CrossRefPubMedGoogle Scholar
  22. 22.
    Penno G, Solini A, Bonora E, Fondelli C, Orsi E, Zerbini G, et al. HbA1c variability as an independent correlate of nephropathy, but not retinopathy, in patients with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events (RIACE) Italian multicenter study. Diabetes Care. 2013;36(8):2301–10.  https://doi.org/10.2337/dc12-2264.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Downie E, Craig ME, Hing S, Cusumano J, Chan AK, Donaghue KC. Continued reduction in the prevalence of retinopathy in adolescents with type 1 diabetes: role of insulin therapy and glycemic control. Diabetes Care. 2011;34(11):2368–73.  https://doi.org/10.2337/dc11-0102.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Kilpatrick ES, Rigby AS, Atkin SL. The effect of glucose variability on the risk of microvascular complications in type 1 diabetes. Diabetes Care. 2006;29(7):1486–90.  https://doi.org/10.2337/dc06-0293.CrossRefPubMedGoogle Scholar
  25. 25.
    Kilpatrick ES, Rigby AS, Atkin SL. A1C variability and the risk of microvascular complications in type 1 diabetes: data from the diabetes control and complications trial. Diabetes Care. 2008;31(11):2198–202.  https://doi.org/10.2337/dc08-0864.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Kilpatrick ES, Rigby AS, Atkin SL. Effect of glucose variability on the long-term risk of microvascular complications in type 1 diabetes. Diabetes Care. 2009;32(10):1901–3.  https://doi.org/10.2337/dc09-0109.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Lachin JM, Bebu I, Bergenstal RM, Pop-Busui R, Service FJ, Zinman B, et al. Association of glycemic variability in type 1 diabetes with progression of microvascular outcomes in the diabetes control and complications trial. Diabetes Care. 2017;40(6):777–83.  https://doi.org/10.2337/dc16-2426.CrossRefPubMedGoogle Scholar
  28. 28.
    Mirani M, Berra C, Finazzi S, Calvetta A, Radaelli MG, Favareto F, et al. Inter-day glycemic variability assessed by continuous glucose monitoring in insulin-treated type 2 diabetes patients on hemodialysis. Diabetes Technol Ther. 2010;12(10):749–53.  https://doi.org/10.1089/dia.2010.0052.CrossRefPubMedGoogle Scholar
  29. 29.
    Lung TW, Petrie D, Herman WH, Palmer AJ, Svensson AM, Eliasson B, et al. Severe hypoglycemia and mortality after cardiovascular events for type 1 diabetic patients in Sweden. Diabetes Care. 2014;37(11):2974–81.  https://doi.org/10.2337/dc14-0405.CrossRefPubMedGoogle Scholar
  30. 30.
    Lind M, Svensson AM, Kosiborod M, Gudbjornsdottir S, Pivodic A, Wedel H, et al. Glycemic control and excess mortality in type 1 diabetes. N Engl J Med. 2014;371(21):1972–82.  https://doi.org/10.1056/NEJMoa1408214.CrossRefPubMedGoogle Scholar
  31. 31.
    Robinson RT, Harris ND, Ireland RH, Macdonald IA, Heller SR. Changes in cardiac repolarization during clinical episodes of nocturnal hypoglycaemia in adults with type 1 diabetes. Diabetologia. 2004;47(2):312–5.  https://doi.org/10.1007/s00125-003-1292-4.CrossRefPubMedGoogle Scholar
  32. 32.
    Frier BM, Schernthaner G, Heller SR. Hypoglycemia and cardiovascular risks. Diabetes Care. 2011;34(Suppl 2):S132–7.  https://doi.org/10.2337/dc11-s220.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Ceriello A, Novials A, Ortega E, La Sala L, Pujadas G, Testa R, et al. Evidence that hyperglycemia after recovery from hypoglycemia worsens endothelial function and increases oxidative stress and inflammation in healthy control subjects and subjects with type 1 diabetes. Diabetes. 2012;61(11):2993–7.  https://doi.org/10.2337/db12-0224.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Abe M, Kalantar-Zadeh K. Haemodialysis-induced hypoglycaemia and glycaemic disarrays. Nat Rev Nephrol. 2015;11(5):302–13.  https://doi.org/10.1038/nrneph.2015.38.CrossRefPubMedGoogle Scholar
  35. 35.
    Raimann JG, Kruse A, Thijssen S, Kuntsevich V, Dabel P, Bachar M, et al. Metabolic effects of dialyzate glucose in chronic hemodialysis: results from a prospective, randomized crossover trial. Nephrol Dial Transplant. 2012;27(4):1559–68.  https://doi.org/10.1093/ndt/gfr520.CrossRefPubMedGoogle Scholar
  36. 36.
    Kazempour-Ardebili S, Lecamwasam VL, Dassanyake T, Frankel AH, Tam FW, Dornhorst A, et al. Assessing glycemic control in maintenance hemodialysis patients with type 2 diabetes. Diabetes Care. 2009;32(7):1137–42.  https://doi.org/10.2337/dc08-1688.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Ricks J, Molnar MZ, Kovesdy CP, Shah A, Nissenson AR, Williams M, et al. Glycemic control and cardiovascular mortality in hemodialysis patients with diabetes: a 6-year cohort study. Diabetes. 2012;61(3):708–15.  https://doi.org/10.2337/db11-1015.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Chu YW, Lin HM, Wang JJ, Weng SF, Lin CC, Chien CC. Epidemiology and outcomes of hypoglycemia in patients with advanced diabetic kidney disease on dialysis: a national cohort study. PLoS One. 2017;12(3):e0174601.  https://doi.org/10.1371/journal.pone.0174601.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    American Diabetes A. 6. Glycemic Targets. Diabetes Care. 2017;40(Suppl 1):S48–56.  https://doi.org/10.2337/dc17-S009.CrossRefGoogle Scholar
  40. 40.
    Bergenstal RM, Gal RL, Connor CG, Gubitosi-Klug R, Kruger D, Olson BA, et al. Racial differences in the relationship of glucose concentrations and hemoglobin A1c levels. Ann Intern Med. 2017;167(2):95–102.  https://doi.org/10.7326/M16-2596.CrossRefPubMedGoogle Scholar
  41. 41.
    UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837–53.CrossRefGoogle Scholar
  42. 42.
    Ansari A, Thomas S, Goldsmith D. Assessing glycemic control in patients with diabetes and end-stage renal failure. Am J Kidney Dis. 2003;41(3):523–31.  https://doi.org/10.1053/ajkd.2003.50114.CrossRefPubMedGoogle Scholar
  43. 43.
    Sharif A, Baboolal K. Diagnostic application of the A(1c) assay in renal disease. J Am Soc Nephrol. 2010;21(3):383–5.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Herman WH, Ma Y, Uwaifo G, Haffner S, Kahn SE, Horton ES, et al. Differences in A1C by race and ethnicity among patients with impaired glucose tolerance in the Diabetes Prevention Program. Diabetes Care. 2007;30(10):2453–7.  https://doi.org/10.2337/dc06-2003.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Herman WH. Do race and ethnicity impact hemoglobin A1c independent of glycemia? J Diabetes Sci Technol. 2009;3(4):656–60.  https://doi.org/10.1177/193229680900300406.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Wright LA, Hirsch IB. Metrics beyond hemoglobin A1C in diabetes management: time in range, hypoglycemia, and other parameters. Diabetes Technol Ther. 2017;19(S2):S16–26.  https://doi.org/10.1089/dia.2017.0029.CrossRefPubMedGoogle Scholar
  47. 47.
    Vos FE, Schollum JB, Coulter CV, Doyle TC, Duffull SB, Walker RJ. Red blood cell survival in long-term dialysis patients. Am J Kidney Dis. 2011;58(4):591–8.  https://doi.org/10.1053/j.ajkd.2011.03.031.CrossRefPubMedGoogle Scholar
  48. 48.
    Nakao T, Matsumoto H, Okada T, Han M, Hidaka H, Yoshino M, et al. Influence of erythropoietin treatment on hemoglobin A1c levels in patients with chronic renal failure on hemodialysis. Intern Med. 1998;37(10):826–30.  https://doi.org/10.2169/internalmedicine.37.826.CrossRefPubMedGoogle Scholar
  49. 49.
    Uzu T, Hatta T, Deji N, Izumiya T, Ueda H, Miyazawa I, et al. Target for glycemic control in type 2 diabetic patients on hemodialysis: effects of anemia and erythropoietin injection on hemoglobin A(1c). Ther Apher Dial. 2009;13(2):89–94.  https://doi.org/10.1111/j.1744-9987.2009.00661.x.CrossRefPubMedGoogle Scholar
  50. 50.
    Spencer DH, Grossman BJ, Scott MG. Red cell transfusion decreases hemoglobin A1c in patients with diabetes. Clin Chem. 2011;57(2):344–6.  https://doi.org/10.1373/clinchem.2010.157321.CrossRefPubMedGoogle Scholar
  51. 51.
    Inaba M, Okuno S, Kumeda Y, Yamada S, Imanishi Y, Tabata T, et al. Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: effect of anemia and erythropoietin injection. J Am Soc Nephrol. 2007;18(3):896–903.  https://doi.org/10.1681/ASN.2006070772.CrossRefPubMedGoogle Scholar
  52. 52.
    Batacchi ZAI, Zelnick L, Robinson-Cohen C, Healy J, Henry C, Robinson N, et al. Accuracy of glycosylated hemoglobin in chronic kidney disease. Diabetes. 2017;67(Suppl 1):LB7.Google Scholar
  53. 53.
    •• Radin MS. Pitfalls in hemoglobin A1c measurement: when results may be misleading. J Gen Intern Med. 2014;29(2):388–94. A detailed review of inaccuracies in A1C measurements.CrossRefPubMedGoogle Scholar
  54. 54.
    Selvin E, Rawlings AM, Grams M, Klein R, Steffes M, Coresh J. Association of 1,5-anhydroglucitol with diabetes and microvascular conditions. Clin Chem. 2014;60(11):1409–18.  https://doi.org/10.1373/clinchem.2014.229427.CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Hirsch IB. Professional flash continuous glucose monitoring as a supplement to A1C in primary care. Postgrad Med. 2017;1–10.Google Scholar
  56. 56.
    Lacy ME, Wellenius GA, Sumner AE, Correa A, Carnethon MR, Liem RI, et al. Association of sickle cell trait with hemoglobin A1c in African Americans. JAMA. 2017;317(5):507–15.  https://doi.org/10.1001/jama.2016.21035.CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Lind M, Polonsky W, Hirsch IB, Heise T, Bolinder J, Dahlqvist S, et al. Continuous glucose monitoring vs conventional therapy for glycemic control in adults with type 1 diabetes treated with multiple daily insulin injections: the GOLD randomized clinical trial. JAMA. 2017;317(4):379–87.  https://doi.org/10.1001/jama.2016.19976.CrossRefPubMedGoogle Scholar
  58. 58.
    Beck RW, Riddlesworth TD, Ruedy K, Ahmann A, Haller S, Kruger D, et al. Continuous glucose monitoring versus usual care in patients with type 2 diabetes receiving multiple daily insulin injections: a randomized trial. Ann Intern Med. 2017;167(6):365–74.  https://doi.org/10.7326/M16-2855.CrossRefPubMedGoogle Scholar
  59. 59.
    Carlson AL, Mullen DM, Bergenstal RM. Clinical use of continuous glucose monitoring in adults with type 2 diabetes. Diabetes Technol Ther. 2017;19(S2):S4–S11.  https://doi.org/10.1089/dia.2017.0024.CrossRefPubMedGoogle Scholar
  60. 60.
    Joubert M, Fourmy C, Henri P, Ficheux M, Lobbedez T, Reznik Y. Effectiveness of continuous glucose monitoring in dialysis patients with diabetes: the DIALYDIAB pilot study. Diabetes Res Clin Pract. 2015;107(3):348–54.  https://doi.org/10.1016/j.diabres.2015.01.026.CrossRefPubMedGoogle Scholar
  61. 61.
    Yeoh EC, Lim BK, Fun S, Tong J, Yeoh LY, Sum CF, et al. Efficacy of self-monitoring of blood glucose versus retrospective continuous glucose monitoring in improving glycaemic control in diabetic kidney disease patients. Nephrology (Carlton). 2016.  https://doi.org/10.1111/nep.12978.
  62. 62.
    •• Hirsch IB, Verderese CA. Professional continuous flash glucose monitoring with ambulatory glucose profile reporting to supplement A1c: rationale and practical implementation. Endocr Pract. 2017. This article explains flash glucose monitoring, its clinical use, data interpretation, and benefits for use in patients with type 1 and type 2 diabetes.Google Scholar
  63. 63.
    Bolinder J, Antuna R, Geelhoed-Duijvestijn P, Kroger J, Weitgasser R. Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. Lancet. 2016;388(10057):2254–63.  https://doi.org/10.1016/S0140-6736(16)31535-5.CrossRefPubMedGoogle Scholar
  64. 64.
    Haak T, Hanaire H, Ajjan R, Hermanns N, Riveline JP, Rayman G. Use of flash glucose-sensing technology for 12 months as a replacement for blood glucose monitoring in insulin-treated type 2 diabetes. Diabetes Ther. 2017;8(3):573–86.  https://doi.org/10.1007/s13300-017-0255-6.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Division of Metabolism, Endocrinology, and NutritionUniversity of WashingtonSeattleUSA

Personalised recommendations